Board summary
Key figures
27,331
Registered population
58.2% aged 18–64
22.9%
Aged 65+
ICB 14.9% · England 17.9%
7.4%
Ethnic minority (non-White)
3.9% Asian · England 9.6%
4.8%
In IMD quintile 1
ICB 40.7% · England 21.0%
~1,389
Core20 residents (est.)
Resident basis; registered basis ~1,326 · see page 3
4,822
Hypertension register
+7.20% in 3 yrs · England +5.60%
237
SMI register
6.5% of Bolton (LAD)'s
634
COPD register
Reviews +24.48% in 3 yrs
Forecast to 2030
5,526
Hypertension patients, 2030
+704 on today
60.1%
QRISK ≥20% on statins, 2030
+3.16pp over 3 yrs
4.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Lipid therapy trails England across high-risk registers.
Lipid-lowering therapy for QRISK ≥ 20% is 53.2% (England 63.6%), alongside gaps in CKD (60.0% vs 70.3%) and diabetes without CVD (64.1% vs 73.2%).
SMI physical health checks lag national averages.
Annual SMI blood pressure recording is 75.9% (England 83.4%), while BMI recording (73.2% vs 82.1%) and psychosis alcohol recording (60.5% vs 81.8%) also trail.
Rapid three-year growth in annual asthma reviews.
Asthma review coverage rose +38.3% over three years (England +4.4%) to 69.6% (England 65.7%), though a scale indicator of about 600 remain unreviewed.
Population, age and ethnicity
Adults aged 65 and over make up 22.9% of registered patients, exceeding benchmarks
Westhoughton Network PCN serves 27,331 registered patients across Unsworth Group Practice (20,186) and Stable Fold Surgery (7,145). Patients aged 65+ account for 22.9% of the list (6,258 patients; Stable Fold Surgery 24.0%, Unsworth Group Practice 22.5%), notably above Bolton (LAD) at 14.7%, the ICB at 14.9%, and England at 17.9%. In associated Census resident areas, 92.6% are White (Bolton 72.0%, ICB 76.4%, England 81.1%) and 3.9% Asian or Asian British. List growth is projected at 0.3% to 2030 (methodology unverified). Age uses registered patients; ethnicity reflects resident Census data.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bolton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bolton LA) | 1,923 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 54.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bolton LA) | 958 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bolton LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 4.8% PCN-wide, dividing outreach between practice concentration and volume
At 4.8%, the Core20 share is below Bolton (LAD) at 47.8%, NHS Greater Manchester ICB at 40.7%, and England at 21.0%, reflecting an average IMD decile of 6.2 (Bolton 4.2, England 5.5). Stable Fold Surgery has the highest Core20 share at 6.8% (486 estimated patients), whereas Unsworth Group Practice has the highest volume at 840 estimated patients (4.2%). Modelled practice estimates rest on list shares rather than direct headcounts. Outreach should balance concentrated engagement where deprivation is densest against routine capacity where volume is largest.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
237
SMI register
0.86% recorded prevalence
167
Learning disability register
0.61% recorded prevalence
5
Care homes, 211 beds
In the PCN catchment
9.8%
Provide unpaid care
Bolton (LAD), Census 2021
The PCN records 167 learning disability patients (0.6%, matching Bolton, ICB, and England at 0.6%) and 237 on the severe mental illness register (0.9%, trailing Bolton at 1.1%, the ICB at 1.1%, and England at 1.0%). Catchment infrastructure includes 5 care homes with 211 beds. Lower recorded SMI prevalence does not establish undiagnosed disease or coding variation, which practice audits could assess.
Severe mental illness: physical health checks
Across 237 SMI patients, annual checks trail England for blood pressure at 75.9% (England 83.4%; Unsworth Group Practice 72.5%), BMI at 73.2% (England 82.1%), and alcohol at 60.5% (England 81.8%). Auditing checks helps address trailing physical health monitoring.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,822
Hypertension register
+7.20%
Register growth, 3 yrs
Bolton (LAD) +4.70% · England +5.60%
+4.61pp
BP control, under 80
≤140/90 · +3.95pp aged 80+
+704
More patients by 2030
Forecast 5,526 (20.16%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.5% (4,822 patients), higher than England (15.2%), Bolton (14.8%), and the ICB (14.4%). Among patients aged under 80, 70.2% meet the blood pressure target (England 67.8%), while overall 70.9% are treated to target (England 70.3%). However, for patients aged 80 and over, blood pressure control trails England at 80.9% versus 81.2% (Unsworth Group Practice at 79.4%, Stable Fold Surgery at 85.0%). Crude prevalence does not adjust for the PCN's older demographic (22.9% aged 65+). Higher prevalence alongside trailing blood pressure control in older cohorts indicates an operational priority to review management for patients aged 80 and over, particularly at Unsworth Group Practice.
Lipids and statins
Lipid-lowering therapy trails England across key risk cohorts: QRISK ≥ 20% at 53.2% (England 63.6%), CKD at 60.0% (England 70.3%), and diabetes without CVD at 64.1% (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than benchmark rates imply, meaning systematic recall audits across these primary prevention cohorts should be prioritised.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 41,153 | £2.30 | £1.94 | £1.86 | £94,652 |
| Cardiovascular (all), 2025 | 68,720 | £4.71 | £3.15 | £3.33 | £323,671 |
In 2026, the PCN prescribed 41,153 lipid-modifying items at £2.30 per item, above England (£1.86), Bolton (£1.81), and the ICB (£1.94). The PCN spent £18,107 more than at England's unit cost across these items. Higher unit costs alongside lower treatment coverage indicate an opportunity to review lipid-modifying prescribing choices while expanding therapy.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+38.26%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.41%
Asthma prevalence, PCN 3-yr % change
Over three years, recorded review rates improved +38.3% for asthma (England +4.4%) and +24.5% for COPD (England +2.8%). Asthma prevalence is 7.6% (1,971 patients; England 6.6%), with 69.6% reviewed in the last 12 months (England 65.7%), leaving about 600 patients unreviewed. COPD prevalence is 2.3% (634 patients; England 1.9%), with reviews at 76.0% (England 76.4%). Prescribing of asthma items for ages 5-19 reaches 1,965 per 1,000 (England 1,488). Review gains are substantial, but unreviewed asthma cohorts warrant proactive scheduling.
Cancer register and children's immunisation
Cancer prevalence is 4.4% (1,206 patients; England 3.8%). Childhood immunisations exceed benchmarks early, with age-2 MMR1 at 98.5% (England 88.3%). However, at age 5, MMR2 and 4-in-1 booster coverage both fall to 91.1%, sitting 3.9 pp below the 95.0% target. Unsworth Group Practice shows a 6.7 pp drop between first (95.6%) and second (88.9%) MMR doses. Pre-school booster recalls are needed to prevent drop-off before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In NHS Greater Manchester ICB (2022), 55.6% of staged cancers (6,491 of 11,679) were diagnosed at stage 1 or 2 (England 55.3%), sitting 19.4 pp below the 75.0% ambition by 2028 (known stage share 70.8%). Reaching this ambition requires about 2,270 extra early diagnoses annually across the ICB. Staging varied between breast (82.5%), lung (40.4%), and oesophagus (22.4%). System staging does not reflect PCN performance, though three-year PCN cancer register growth was +4.8% (England +9.0%). Slower register growth could reflect coding or referral patterns, which local audits could test.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Bolton NHS Foundation Trust achieved 80.5% on the 28-day faster diagnosis standard, exceeding the 75.0% standard, Manchester University NHS Foundation Trust (80.1%), the ICB (79.5%), and England (79.3%), while behind Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust (82.8%). Bolton achieved 69.7% on the 62-day standard, trailing 15.3 pp below the 85.0% target (ICB 75.7%, England 71.2%). For diagnostics, 15.8% waited 6+ weeks at Bolton (England 23.1%), including computed tomography at 19.4% and colonoscopy at 1.3%. These trust metrics reflect secondary care pathways rather than PCN performance.
| Pathways within standard (%) | Bolton | Wrightington, Wigan and Leigh | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 82.80 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 89.04 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 76.78 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Wrightington, Wigan and Leigh | Manchester | England |
|---|---|---|---|---|
| MRI | 2.05 | 0.49 | 11.68 | 21.40 |
| CT | 19.40 | 7.78 | 14.66 | 9.92 |
| Echocardiography | 3.48 | 24.37 | 4.91 | 28.48 |
| Colonoscopy | 1.33 | 6.10 | 4.51 | 30.83 |
| Gastroscopy | 2.06 | 12.54 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.78 | 14.36 | 8.98 | 23.14 |
| Community services activity | Bolton residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 49,315 | 573,310 |
| Referrals | 4,075 | 94,470 |
| Patients with a contact | 17,765 | 183,535 |
Community services (residents of Bolton), Jun 2026 (provisional). In Jun 2026, 17,765 Bolton residents had a recorded community care contact across 49,315 contacts and 49,135 activities (ICB: 183,535 patients; 573,310 contacts). Bolton recorded 4,075 community referrals for 3,330 patients. Adults aged 65+ accounted for 51.6% of borough contacts (25,460). High community contact volume among older residents underscores the importance of coordinated primary and community nursing links for managing post-diagnosis cancer and frailty care.
Practice variation and patient experience
Phone access diverges by 23.3 pp across practices while clinical achievement remains high
In 2025/26, overall QOF achievement was 94.8% at Unsworth Group Practice and 90.6% at Stable Fold Surgery (England 92.5%). Vaccination and immunisation domain achievement reached 74.7% at Unsworth Group Practice and 61.4% at Stable Fold Surgery (England 55.2%, a 13.3 pp range). High points delivery demonstrates recorded clinical activity, though points do not establish unique population reach.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Stable Fold | 101 | 6.8 | 44.7% | 73.9% | 77.1% |
| Unsworth | 77 | 4.2 | 21.4% | 75.9% | 70.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Diabetes control and depression growth lagged England while respiratory reviews expanded rapidly
Between 2023 and 2025, three-year relative growth trailed England most for depression prevalence (+0.7% vs +7.7% England, Bolton +6.8%) and non-frail diabetes HbA1c control (+0.4% vs +4.4% England, Bolton +1.9%). Hypertension blood pressure recording also rose more slowly (+1.8% vs +3.6% England). In contrast, asthma reviews rose +38.3% (England +4.4%), COPD reviews rose +24.5% (England +2.8%), and learning disability prevalence rose +23.1% (England +5.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Depression register
Cancer register
Diabetes HbA1c control
Hypertension BP reading
Heart failure reviews
Asthma reviews
COPD reviews
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bolton (LAD) | Asset | PCN | Bolton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 5 (211 beds) | n/a | Schools (catchment) | 20 | n/a |
| Children's centres | 1 | 18 | Places of worship | 15 | 144 |
| Libraries | 2 | 7 | Primary schools (LA maintained) | 9 | 61 |
| Primary academies | 1 | 32 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Lipid therapy recall and prescribing review
Lipid-lowering therapy trails England for QRISK ≥ 20% at 53.2% (England 63.6%), CKD at 60.0% (England 70.3%), and diabetes without CVD at 64.1% (England 73.2%). Lipid-modifying items cost £2.30 (England £1.86), £18,107 more than England's unit cost across 41,153 items. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 2
Combined SMI physical health check recall
Across 237 SMI patients (0.9% prevalence vs 1.0% England), annual BP checks sit at 75.9% (England 83.4%; Unsworth Group Practice 72.5%), BMI at 73.2% (England 82.1%), and psychosis alcohol recording at 60.5% (England 81.8%). For discussion: introduce a single-appointment SMI check template and proactive outreach, starting at Unsworth Group Practice. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Structured recall for unreviewed asthma patients
Asthma review coverage reached 69.6% of the 1,971 register (England 65.7%, Bolton (LAD) 66.6%) after +38.3% three-year growth, leaving a scale indicator of about 600 patients without a recorded review. For discussion: sustain momentum by offering flexible or remote asthma review slots aligned with Core20 outreach. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive older adult care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older cohort blood pressure review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster and MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer referral and safety netting (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Telephony and triage workflow review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Lipid therapy recall and prescribing review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
| Option 2 · Combined SMI physical health check recall (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Structured recall for unreviewed asthma patients (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
